The Food and Drug Administration yesterday updated its fact sheets for providers and recipients and caregivers for the Johnson & Johnson COVID-19 vaccine, with each revised document outlining a contraindication for the vaccine’s administration to individuals with histories of thrombosis with thrombocytopenia following doses of this or any other adenovirus-vectored COVID-19 vaccine. The updated fact sheets discuss the risk of thrombosis with thrombocytopenia syndrome following vaccination, an ailment that has been observed in males and females 18 years of age and older, with females 30-49 years of age experiencing the highest reporting rate (approximately one case per 100,000 administered doses). Overall, thrombosis with thrombocytopenia syndrome is fatal in approximately one out of seven cases.

Related News Articles

Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…